Literature DB >> 9271860

Oxacillin-hydrolyzing beta-lactamase involved in resistance to imipenem in Acinetobacter baumannii.

M Hornstein1, C Sautjeau-Rostoker, J Péduzzi, A Vessières, L T Hong, M Barthélémy, M Scavizzi, R Labia.   

Abstract

Acinetobacter baumannii strain A148, a clinical isolate resistant to imipenem (MIC = 32 mg l-1), synthesized two beta-lactamases with pIs 6.3 and > 9.2. The pI 6.3 enzyme hydrolyzed the penicillins, including isoxazoylpenicillins, first-, second- and, to a lesser extent, third-generation cephalosporins. It was inhibited by chloride ions and by the penem beta-lactamase inhibitor BRL 42715. Clavulanate was a weak inhibitor and EDTA did not affect the beta-lactamase activity. This enzyme also hydrolyzed imipenem with a catalytic efficiency (Kcat/Km) of 1500 mM-1 s-1. Moreover, this purified beta-lactamase produced a positive microbiological clover-leaf test with imipenem. Therefore, the pI 6.3 beta-lactamase was considered to be involved in the imipenem resistance of A. baumannii strain A148.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271860     DOI: 10.1111/j.1574-6968.1997.tb12593.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  11 in total

1.  Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92.

Authors:  H M Donald; W Scaife; S G Amyes; H K Young
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

2.  Detection of carbapenemase-producing Acinetobacter baumannii in a hospital.

Authors:  A Takahashi; S Yomoda; I Kobayashi; T Okubo; M Tsunoda; S Iyobe
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 3.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

4.  Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii.

Authors:  M Afzal-Shah; N Woodford; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 5.  Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

Authors:  J A Barman Balfour; R H Foster
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

6.  Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases.

Authors:  G Bou; G Cerveró; M A Domínguez; C Quereda; J Martínez-Beltrán
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

7.  IMP-4, a novel metallo-beta-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998.

Authors:  Y W Chu; M Afzal-Shah; E T Houang; M I Palepou; D J Lyon; N Woodford; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain.

Authors:  G Bou; A Oliver; J Martínez-Beltrán
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

9.  Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis.

Authors:  R Bonnet; H Marchandin; C Chanal; D Sirot; R Labia; C De Champs; E Jumas-Bilak; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

10.  Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in korea.

Authors:  Byung-Chan Jeon; Seok Hoon Jeong; Il Kwon Bae; Su Bong Kwon; Kyungwon Lee; Dongeun Young; Jung Hun Lee; Jae Seok Song; Sang Hee Lee
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.